RESUMO
BACKGROUND: Calcium-free (Ca-free) solutions are theoretically the most ideal for regional citrate anticoagulation (RCA) in continuous renal replacement therapy (CRRT). However, the majority of medical centers in China had to make a compromise of using commercially available calcium-containing (Ca-containing) solutions instead of Ca-free ones due to their scarcity. This study was designed to probe into the potential of Ca-containing solution as a secure and efficient substitution for Ca-free solutions. METHODS: In this prospective, randomized single-center trial, 99 patients scheduled for CRRT were randomly assigned in a 1:1:1 ratio to one of three treatment groups: continuous veno-venous hemodialysis Ca-free dialysate (CVVHD Ca-free) group, continuous veno-venous hemodiafiltration calcium-free dialysate (CVVHDF Ca-free) group, and continuous veno-venous hemodiafiltration Ca-containing dialysate (CVVHDF Ca-containing) group at cardiac intensive care unit (CICU). The primary endpoint was the incidence of metabolic complications. The secondary endpoints included premature termination of treatment, thrombus of filter, and bubble trap after the process. RESULTS: The incidence of citrate accumulation (18.2% vs. 12.1% vs. 21.2%) and metabolic alkalosis (12.1% vs. 0% vs. 9.1%) did not significantly differ among three groups (p > 0.05 for both). The incidence of premature termination was comparable among the groups (18.2% vs. 9.1% vs. 9.1%, p = 0.582). The thrombus level of the filter and bubble trap was similar in the three groups (p > 0.05 for all). CONCLUSIONS: In RCA-CRRT for CICU population, RCA-CVVHDF with Ca-containing solutions and traditional RCA with Ca-free solutions had a comparable safety and feasibility. TRIAL REGISTRATION: ChiCTR2100048238 in the Chinese Clinical Trial Registry.
Assuntos
Anticoagulantes , Ácido Cítrico , Terapia de Substituição Renal Contínua , Soluções para Diálise , Estudos de Viabilidade , Humanos , Feminino , Masculino , Terapia de Substituição Renal Contínua/métodos , Pessoa de Meia-Idade , Anticoagulantes/administração & dosagem , Estudos Prospectivos , Ácido Cítrico/administração & dosagem , Soluções para Diálise/administração & dosagem , Soluções para Diálise/química , Idoso , China , Cálcio/sangue , Cálcio/administração & dosagem , Injúria Renal Aguda/terapiaRESUMO
BACKGROUND: Debate continues as to the optimum hemodialysis (HD) dialysate calcium concentration. Although current guidelines advocate 1.25-1.5 mmol/L, some investigators have suggested these may cause calcium gains. As such we investigated whether using dialysate calcium of 1.25 mmol/L risked calcium gains, and whether there were differences between hemodiafiltration and high flux HD. METHODS: We continuously collect an aliquot of effluent dialysate during dialysis sessions, and calculated dialysis calcium mass balance by the difference between the amount of calcium delivered as fresh dialysate and that lost in effluent dialysate. RESULTS: We studied 106 stable outpatients, 64% male, mean age 64.4 ± 16.2 years, median dialysis vintage 32 (22-60) months. Most sessions (69%) used a 1.0 mmol/L calcium dialysate, with a median sessional loss of 13.7 (11.5-17.1) mmol, whereas using 1.25 mmol/L the median loss was 7.4 (4.9-10.1) mmol, but with 6.9% had a positive balance (p = 0.031 vs dialysate calcium 1.0 mmol/L). Most patients (85.8%) were treated by hemodiafiltration, but there was no difference in sessional losses (11.7 (8.4-15.8) vs 13.5 (8.1-16.8)) with high flux HD. Dialysis sessional calcium balance was associated with the use of lower dialysate calcium concentration (ß -19.5, 95% confidence limits (95%CL) -27.7 to -11.3, p < 0.001), and sessional duration (ß 0.07 (95% CL) 0.03-012, p = 0.002). CONCLUSION: Ideally, the choice of dialysate calcium should be individualized, but clinicians should be aware, that even when using a dialysate calcium of 1.25 mmol/L, some patients are at risk of a calcium gain during hemodiafiltration and high-flux hemodialysis.
Assuntos
Cálcio , Soluções para Diálise , Hemodiafiltração , Diálise Renal , Humanos , Masculino , Pessoa de Meia-Idade , Hemodiafiltração/métodos , Feminino , Cálcio/análise , Idoso , Diálise Renal/métodos , Diálise Renal/efeitos adversos , Soluções para Diálise/química , Idoso de 80 Anos ou mais , Falência Renal Crônica/terapia , Soluções para Hemodiálise/químicaRESUMO
BACKGROUND: Regional anticoagulation in hemodialysis avoids the use of heparin, which is responsible for both hemorrhagic and non-hemorrhagic complications. Typically, blood is decalcified by injecting citrate into the arterial line of the extracorporeal circuit. Calcium-free dialysate improves anticoagulation efficacy but requires injection of a calcium-containing solution into the venous line and strict monitoring of blood calcium levels. Recent improvements have made regional anticoagulation with calcium-free dialysate safer and easier. OBSERVATIONS: (1) Adjusting the calcium injection rate to ionic dialysance avoids the risk of dyscalcemia, thus making unnecessary the monitoring of blood calcium levels. This adjustment could be carried out automatically by the hemodialysis monitor. (2) As calcium-free dialysate reduces the amount of citrate required, this can be supplied by dialysate obtained from currently available concentrates containing citric acid. This avoids the need for citrate injection and the risk of citrate overload. (3) Calcium-free dialysate no longer needs the dialysate acidification required for avoiding calcium carbonate precipitation in bicarbonate-containing dialysate. CONCLUSIONS: Regional anticoagulation with calcium-free dialysate enables an acid- and heparin-free procedure that is more biocompatible and environmentally friendly than conventional bicarbonate hemodialysis. The availability of specific acid-free concentrates and adapted hemodialysis monitors is required to extend this procedure to maintenance hemodialysis.
Assuntos
Anticoagulantes , Cálcio , Diálise Renal , Humanos , Diálise Renal/métodos , Diálise Renal/instrumentação , Anticoagulantes/administração & dosagem , Soluções para Diálise/química , Ácido Cítrico/administração & dosagem , Ácido Cítrico/química , Coagulação Sanguínea/efeitos dos fármacos , Soluções para Hemodiálise/químicaRESUMO
BACKGROUND: Normothermic machine perfusion (NMP) allows for the assessment and resuscitation of ex-vivo human livers prior to transplantation. Commercially available NMP systems are closed circuits that accumulate metabolic waste and cytokines over time, potentially limiting organ preservation times. Dialysis has been proposed as a method to remove waste and excess fluid from such systems. This study aimed to demonstrate the utility of integrating dialysis into a commercially available system by quantifying solute removal. METHODS: A dialysis filter was attached in parallel to a commercially available liver perfusion system. Three livers declined for transplantation were split before undergoing long-term NMP with blood using the modified system. During perfusion, dialysate flow rates were set in the range of 100-600 mL/h for short periods of time. At each flow rate, perfusate and spent dialysate samples were collected and analyzed for solute clearance. RESULTS: The addition of dialysis to a commercial NMP system removed water-soluble waste and helped regulate electrolyte concentrations. Interleukin-6 was successfully removed from the perfusate. Solute clearance was proportional to dialysate flow rate. A guide for our perfusion setup was created for the appropriate selection of dialysis flow rates and duration based on real-time perfusate composition. CONCLUSIONS: Dialysis circuits can efficiently remove waste and regulate perfusate composition, and can be easily incorporated to improve the performance of commercially available systems. Quantification of the effect of dialysis on perfusate composition enables refined dialysis control to optimize electrolyte profiles and avoid the over- or under-correction of key solutes.
Assuntos
Fígado , Preservação de Órgãos , Perfusão , Diálise Renal , Humanos , Perfusão/métodos , Perfusão/instrumentação , Preservação de Órgãos/métodos , Preservação de Órgãos/instrumentação , Diálise Renal/instrumentação , Diálise Renal/métodos , Fígado/irrigação sanguínea , Transplante de Fígado/métodos , Masculino , Soluções para Diálise/química , Pessoa de Meia-Idade , FemininoRESUMO
Excessive albumin losses during HC (haemocatharsis) are considered a potential cause of hypoalbuminemia-a key risk factor for mortality. This review on total albumin losses considers albumin "leaking" into the dialysate and losses due to protein/membrane interactions (i.e. adsorption, "secondary membrane formation" and denaturation). The former are fairly easy to determine, usually varying at the level of ~ 2 g to ~ 7 g albumin loss per session. Such values, commonly accepted as representative of the total albumin losses, are often quoted as limits/standards of permissible albumin loss per session. On albumin mass lost due to adsorption/deposition, which is the result of complicated interactions and rather difficult to determine, scant in vivo data exist and there is great uncertainty and confusion regarding their magnitude; this is possibly responsible for neglecting their contribution to the total losses at present. Yet, many relevant in vitro studies suggest that losses of albumin due to protein/membrane interactions are likely comparable to (or even greater than) those due to leaking, particularly in the currently favoured high-convection HDF (haemodiafiltration) treatment. Therefore, it is emphasised that top research priority should be given to resolve these issues, primarily by developing appropriate/facile in vivo test-methods and related analytical techniques.
Assuntos
Hemodiafiltração , Hipoalbuminemia , Albumina Sérica , Humanos , Soluções para Diálise/química , Hemodiafiltração/métodos , Diálise Renal , Albumina Sérica/análiseRESUMO
The choice of dialysate buffer in hemodialysis is crucial, with acetate being widely used despite complications. Citrate has emerged as an alternative because of its favorable effects, yet concerns persist about its impact on calcium and magnesium levels. This study investigates the influence of citrate dialysates (CDs) with and without additional magnesium supplementation on CKD-MBD biomarkers and assesses their ability to chelate divalent metals compared to acetate dialysates (ADs). A prospective crossover study was conducted in a single center, involving patients on thrice-weekly online hemodiafiltration (HDF). The following four dialysates were compared: two acetate-based and two citrate-based. Calcium, magnesium, iPTH, iron, selenium, cadmium, copper, zinc, BUN, albumin, creatinine, bicarbonate, and pH were monitored before and after each dialysis session. Seventy-two HDF sessions were performed on eighteen patients. The CDs showed stability in iPTH levels and reduced post-dialysis total calcium, with no significant increase in adverse events. Magnesium supplementation with CDs prevented hypomagnesemia. However, no significant differences among dialysates were observed in the chelation of other divalent metals. CDs, particularly with higher magnesium concentrations, offer promising benefits, including prevention of hypomagnesemia and stabilization of CKD-MBD parameters, suggesting citrate as a viable alternative to acetate. Further studies are warranted to elucidate long-term outcomes and optimize dialysate formulations. Until then, given our results, we recommend that when a CD is used, it should be used with a 0.75 mmol/L Mg concentration rather than a 0.5 mmol/L one.
Assuntos
Acetatos , Ácido Cítrico , Estudos Cross-Over , Hemodiafiltração , Magnésio , Humanos , Masculino , Feminino , Hemodiafiltração/métodos , Pessoa de Meia-Idade , Magnésio/administração & dosagem , Idoso , Estudos Prospectivos , Soluções para Diálise/química , CálcioRESUMO
PURPOSE: Incremental peritoneal dialysis (IPD) could decrease unfavorable glucose exposure results and preserve (RKF). However, there is no standardization of dialysis prescriptions for patients undergoing IPD. We designed a prospective observational multi-center study with a standardized IPD prescription to evaluate the effect of IPD on RKF, metabolic alterations, blood pressure control, and adverse outcomes. METHODS: All patients used low GDP product (GDP) neutral pH solutions in both the incremental continuous ambulatory peritoneal dialysis (ICAPD) group and the retrospective standard PD (sPD) group. IPD patients started treatment with three daily exchanges five days a week. Control-group patients performed four changes per day, seven days a week. RESULTS: A total of 94 patients (47 IPD and 47 sPD) were included in this study. The small-solute clearance and mean blood pressures were similar between both groups during follow-up. The weekly mean glucose exposure was significantly higher in sPD group than IPD during the follow-up (p < 0.001). The patients with sPD required more phosphate-binding medications compared to the IPD group (p = 0.05). The rates of peritonitis, tunnel infection, and hospitalization frequencies were similar between groups. Patients in the sPD group experienced more episodes of hypervolemia compared to the IPD group (p = 0.007). The slope in RKF in the 6th month was significantly higher in the sPD group compared to the IPD group (65% vs. 95%, p = 0.001). CONCLUSION: IPD could be a rational dialysis method and provide non-inferior dialysis adequacy compared to full-dose PD. This regimen may contribute to preserving RKF for a longer period.
Assuntos
Soluções para Diálise , Glucose , Diálise Peritoneal , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Estudos Prospectivos , Concentração de Íons de Hidrogênio , Idoso , Soluções para Diálise/química , Resultado do Tratamento , Diálise Peritoneal Ambulatorial Contínua , Falência Renal Crônica/terapia , Estudos Retrospectivos , AdultoRESUMO
INTRODUCTION: In some studies, the peritoneal solute transfer rate (PSTR) through the peritoneal membrane has been related to an increased risk of mortality. It has been observed in the literature that those patients with rapid diffusion of solutes through the peritoneal membrane (high/fast transfer) and probably those with high average transfer characterized by the Peritoneal Equilibrium Test (PET) are associated with higher mortality compared to those patients who have a slow transfer rate. However, some authors have not documented this fact. In the present study, we want to evaluate the (etiological) relationship between the characteristics of peritoneal membrane transfer and mortality and survival of the technique in an incident population on peritoneal dialysis in RTS Colombia during the years 2007-2017 using a competing risk model. MATERIALS AND METHODS: A retrospective cohort study was carried out at RTS Colombia in the period between 2007 and 2017. In total, there were 8170 incident patients older than 18 years, who had a Peritoneal Equilibration Test (PET) between 28 and 180 days from the start of therapy. Demographic, clinical, and laboratory variables were evaluated. The (etiological) relationship between the type of peritoneal solute transfer rate at the start of therapy and overall mortality and technique survival were analyzed using a competing risk model (cause-specific proportional hazard model described by Royston-Lambert). RESULTS: Patients were classified into four categories based on the PET result: Slow/Low transfer (16.0%), low average (35.4%), high average (32.9%), and High/Fast transfer (15.7%). During follow-up, with a median of 730 days, 3025 (37.02%) patients died, 1079 (13.2%) were transferred to hemodialysis and 661 (8.1%) were transplanted. In the analysis of competing risks, adjusted for age, sex, presence of DM, HTA, body mass index, residual function, albumin, hemoglobin, phosphorus, and modality of PD at the start of therapy, we found cause-specific HR (HRce) for high/fast transfer was 1.13 (95% CI 0.98-1.30) pâ¯=â¯0.078, high average 1.08 (95% CI 0.96-1.22) pâ¯=â¯0.195, low average 1.09 (95% CI 0.96-1.22) pâ¯=â¯0.156 compared to the low/slow transfer rate. For technique survival, cause-specific HR for high/rapid transfer of 1.22 (95% CI 0.98-1.52) pâ¯=â¯0.66, high average HR was 1.10 (95% CI 0.91-1.33) pâ¯=â¯0.296, low average HR of 1.03 (95% CI 0.85-1.24) pâ¯=â¯0.733 compared with the low/slow transfer rate, adjusted for age, sex, DM, HTA, BMI, residual renal function, albumin, phosphorus, hemoglobin, and PD modality at start of therapy. Non-significant differences. CONCLUSIONS: When evaluating the etiological relationship between the type of peritoneal solute transfer rate and overall mortality and survival of the technique using a competing risk model, we found no etiological relationship between the characteristics of peritoneal membrane transfer according to the classification given by Twardowski assessed at the start of peritoneal dialysis therapy and overall mortality or technique survival in adjusted models. The analysis will then be made from the prognostic model with the purpose of predicting the risk of mortality and survival of the technique using the risk subdistribution model (Fine & Gray).
Assuntos
Diálise Peritoneal , Insuficiência Renal Crônica , Humanos , Colômbia/epidemiologia , Estudos Retrospectivos , Masculino , Feminino , Diálise Peritoneal/mortalidade , Pessoa de Meia-Idade , Insuficiência Renal Crônica/terapia , Insuficiência Renal Crônica/mortalidade , Adulto , Fatores de Tempo , Idoso , Peritônio/metabolismo , Taxa de Sobrevida , Soluções para Diálise/químicaRESUMO
ABSTRACT Introduction: In hemodialysis, patients are exposed to a large volume of water, which may lead to fatal risks if not meeting quality standards. This study aimed to validate an alternative method for monitoring microbiological quality of treated water and assess its applicability in dialysis and dialysate analysis, to allow corrective actions in real-time. Methods: Validation and applicability were analyzed by conventional and alternative methods. For validation, E. coli standard endotoxin was diluted with apyrogenic water in five concentrations. For the applicability analysis, treated water for dialysis was collected from different points in the treatment system (reverse osmosis, drainage canalization at the storage tank bottom, reuse, and loop), and dialysate was collected from four machines located in different rooms in the hemodialysis sector. Results: The validation results were in accordance with the Brazilian Pharmacopoeia acceptance criteria, except for the last two concentrations analyzed. In addition, the ruggedness criterion performed under the US Pharmacopoeia was in agreement with the results. Discussion: A limiting factor in the applicability analysis was the absence of the endotoxin maximum permitted level in dialysate by the Brazilian legislation. When comparing the analysis time, the alternative method was more time-consuming than the conventional one. This suggests that the alternative method is effective in the case of few analyses, that is, real-time analyses, favoring corrective actions promptly. On the other hand, it does not support the implementation of the alternative method in a laboratory routine due to the high demand for analyses.
RESUMO Introdução: Na hemodiálise, os pacientes são expostos a um grande volume de água, o que pode levar a riscos fatais se não cumprir com padrões de qualidade. Este estudo teve como objetivo validar um método alternativo para monitorar a qualidade microbiológica da água tratada e avaliar sua aplicabilidade em análises de diálise e dialisato, para permitir ações corretivas em tempo real. Métodos: A validação e aplicabilidade foram analisadas por métodos convencionais e alternativos. Para validação, a endotoxina padrão de E. coli foi diluída com água apirogênica em cinco concentrações. Para a análise de aplicabilidade, a água tratada para diálise foi coletada em diferentes pontos do sistema de tratamento (osmose reversa, canalização de drenagem no fundo do tanque de armazenamento, reutilização e circuito) e o dialisato foi coletado em quatro máquinas localizadas em diferentes salas do setor de hemodiálise. Resultados: Os resultados da validação obedeceram aos critérios de aceitação da Farmacopeia Brasileira, com exceção das duas últimas concentrações analisadas. Além disso, o critério de robustez realizado sob a Farmacopeia dos EUA estava de acordo com os resultados. Discussão: Um fator limitante na análise de aplicabilidade foi a ausência do nível máximo permitido de endotoxina no dialisato pela legislação brasileira. Ao comparar o tempo de análise, o método alternativo consumiu mais tempo que o convencional. Isso sugere que o método alternativo é eficaz no caso de poucas análises, ou seja, análises em tempo real, favorecendo ações corretivas imediatamente. Por outro lado, não suporta a implementação do método alternativo em uma rotina de laboratório devido à alta demanda por análises.
Assuntos
Humanos , Qualidade da Água/normas , Água/efeitos adversos , Soluções para Diálise/análise , Diálise Renal/normas , Farmacopeias como Assunto , Microbiologia da Água/normas , Brasil/epidemiologia , Água/química , Soluções para Diálise/química , Diálise Renal/estatística & dados numéricos , Purificação da Água/métodos , Endotoxinas/análise , Escherichia coli/crescimento & desenvolvimentoRESUMO
Abstract Fluid volume and hemodynamic management in hemodialysis patients is an essential component of dialysis adequacy. Restoring salt and water homeostasis in hemodialysis patients has been a permanent quest by nephrologists summarized by the 'dry weight' probing approach. Although this clinical approach has been associated with benefits on cardiovascular outcome, it is now challenged by recent studies showing that intensity or aggressiveness to remove fluid during intermittent dialysis is associated with cardiovascular stress and potential organ damage. A more precise approach is required to improve cardiovascular outcome in this high-risk population. Fluid status assessment and monitoring rely on four components: clinical assessment, non-invasive instrumental tools (e.g., US, bioimpedance, blood volume monitoring), cardiac biomarkers (e.g. natriuretic peptides), and algorithm and sodium modeling to estimate mass transfer. Optimal management of fluid and sodium imbalance in dialysis patients consist in adjusting salt and fluid removal by dialysis (ultrafiltration, dialysate sodium) and by restricting salt intake and fluid gain between dialysis sessions. Modern technology using biosensors and feedback control tools embarked on dialysis machine, with sophisticated analytics will provide direct handling of sodium and water in a more precise and personalized way. It is envisaged in the near future that these tools will support physician decision making with high potential of improving cardiovascular outcome.
Resumo O volume de fluidos e o controle hemodinâmico em pacientes em hemodiálise é um componente essencial da adequação da diálise. A restauração da homeostase do sal e da água em pacientes em hemodiálise tem sido uma busca constante por parte dos nefrologistas, no que condiz à abordagem do "peso seco. Embora essa abordagem clínica tenha sido associada a benefícios no desfecho cardiovascular, recentemente tem sido questionada por estudos que mostram que a intensidade ou agressividade para remover fluidos durante a diálise intermitente está associada a estresse cardiovascular e dano potencial a órgãos.para remover fluidos durante a diálise intermitente está associada a estresse cardiovascular e dano potencial a órgãos. Uma abordagem mais precisa é necessária para melhorar o desfecho cardiovascular nessa população de alto risco. A avaliação e monitorização do estado hídrico baseiam-se em quatro componentes: avaliação clínica, ferramentas instrumentais não invasivas (por exemplo, US, bioimpedância, monitorização do volume sanguíneo), biomarcadores cardíacos (e.g. peptídeos natriuréticos), algoritmos e modelagem de sódio para estimar a transferência de massa. O manejo otimizado do desequilíbrio hídrico e de sódio em pacientes dialíticos consiste em ajustar a remoção de sal e líquido por diálise (ultrafiltração, dialisato de sódio), e restringir a ingestão de sal e o ganho de líquido entre as sessões de diálise. Tecnologia moderna que utiliza biosensores e ferramentas de controle de feedback, hoje parte da máquina de diálise, com análises sofisticadas, proporcionam o manejo direto sobre o sódio e a água de uma maneira mais precisa e personalizada. Prevê-se no futuro próximo que essas ferramentas poderão auxiliar na tomada de decisão do médico, com alto potencial para melhorar o resultado cardiovascular.
Assuntos
Humanos , Sódio/metabolismo , Diálise Renal/efeitos adversos , Hemodinâmica/fisiologia , Homeostase/fisiologia , Falência Renal Crônica/terapia , Equilíbrio Hidroeletrolítico/fisiologia , Pressão Sanguínea/fisiologia , Algoritmos , Biomarcadores/metabolismo , Soluções para Diálise/química , Sistema Cardiovascular/fisiopatologia , Diálise Renal/normas , Resultado do Tratamento , Descondicionamento Cardiovascular , Nefrologistas/estatística & dados numéricos , Falência Renal Crônica/fisiopatologiaRESUMO
Introduction: Continuous exposition of the peritoneal membrane to conventional dialysis solutions is an important risk factor for inducing structural and functional alterations. Objective: To compare in vitro mouse fibroblast NIH-3T3 cell viability after exposition to a neutral pH dialysis solution in comparison to cells exposed to a standard solution. Methods: Experimental study to compare the effects of a conventional standard or a neutral-pH, low-glucose degradation products peritoneal dialysis solution on the viability of exposed fibroblasts in cell culture. Both solutions were tested in all the commercially available glucose concentrations. Cell viability was evaluated with tetrazolium salt colorimetric assay. Results: Fibroblast viability was significantly superior in the neutral pH solution in comparison to control, in all three glucose concentrations (Optical density in nm-means ± SD: 1.5% 0.295 ± 0.047 vs. 0.372 ± 0.042, p < 0.001; 2.3% 0.270 ± 0.036 vs. 0.337 ± 0.051, p < 0.001; 4.25% 0.284 ± 0.037 vs. 0.332 ± 0.032, p < 0.001; control vs. neutral pH respectively, Student t Test). There was no significant difference in cell viability between the three concentrations of glucose when standard solution was used (ANOVA p = 0.218), although cell viability was higher after exposition to neutral pH peritoneal dialysis fluid at 1.5% in comparison to 2.3 and 4.25% glucose concentrations (ANOVA p = 0.008: Bonferroni 1.5% vs. 2.3% p = 0.033, 1.5% vs. 4.25% p = 0.014, 2.3% vs. 4.25% p = 1.00). Conclusion: Cell viability was better in neutral pH dialysis solution, especially in the lower glucose concentration. A more physiological pH and lower glucose degradation products may be responsible for such results. .
Introdução: A exposição contínua da membrana peritoneal a soluções convencionais de diálise é um importante fator de risco para induzir alterações estruturais e funcionais. Objetivo: Comparar a viabilidade in vitro dos fibroblastos NIH-3T3 de camundongo após exposição à solução de diálise com pH neutro com células expostas à solução padrão. Métodos: Estudo experimental; ambas as soluções foram testadas em todas as concentrações de glicose comercialmente disponíveis. A viabilidade celular foi avaliada por ensaio colorimétrico de sal tetrazólio. Resultados: A viabilidade de fibroblastos foi melhor na solução de pH neutro em relação ao controle nas três concentrações de glicose (densidade óptica em nm-médias ± DP: 1,5% 0,295 ± 0,047 vs. 0,372 ± 0,042, p < 0,001; 2,3% 0,270 ± 0,036 vs. 0,337 ± 0,051, p < 0,001; 4,25% 0,284 ± 0,037 vs. 0,332 ± 0,032, p < 0,001; controle vs. pH neutro respectivamente, teste t de Student). Não houve diferença significativa na viabilidade celular entre as três concentrações de glicose quando solução padrão foi utilizada (ANOVA p = 0,218), embora a viabilidade celular tenha sido superior após exposição aos fluidos de diálise peritoneal neutros, pH 1,5% em comparação com 2,3 e 4,25% de concentrações de glicose (ANOVA p = 0,008: Bonferroni 1,5% vs. 2,3% p = 0,033, 1,5% vs. 4,25% p = 0,014, 2,3% vs. 4,25% p = 1,0). Conclusão: A viabilidade celular foi melhor em solução neutra de pH de diálise, especialmente nas menores concentrações de glicose. O pH fisiológico e com menos produtos de degradação de glicose podem ser responsáveis por estes resultados. .
Assuntos
Animais , Camundongos , Soluções para Diálise/química , Soluções para Diálise/farmacologia , Fibroblastos/efeitos dos fármacos , Diálise Peritoneal , Sobrevivência Celular/efeitos dos fármacos , Concentração de Íons de HidrogênioRESUMO
INTRODUÇÃO: Hipoglicemia pode ocorrer durante hemodiálise em pacientes diabéticos renais crônicos quando se utiliza dialisato sem glicose. Com soluções de diálise contendo glicose a 90 mg/dL ou mais, isto pode ser prevenido, mas esses pacientes diabéticos podem apresentar glicemias intradialíticas muito elevadas. OBJETIVO: Nosso estudo testou um dialisato com taxas mais reduzidas de glicose tentando prevenir tanto hipo como hiperglicemia nesses pacientes. MÉTODOS: Vinte indivíduos diabéticos de nossa unidade de hemodiálise foram submetidos a três sessões com soluções de diálise com diferentes concentrações de glicose - 55 mg/dL (Fase 55) e 90 mg/dL (Fase 90) - e uma solução sem glicose (Fase ZERO). Glicemias foram medidas em cinco momentos durante cada sessão - antes e aos 30, 60, 150 e 240 min. Resultados inferiores a 70 mg/dL foram considerados como hipoglicemia. RESULTADOS: Três pacientes apresentaram seis episódios de hipoglicemia na Fase 55, mas nenhum paciente apresentou qualquer episódio na Fase 90. Na Fase ZERO, cinco pacientes apresentaram sete episódios. CONCLUSÃO: O dialisato com baixo teor de glicose (55 mg/dL) não preveniu episódios de hipoglicemia durante hemodiálise em pacientes diabéticos, um achado similar ao obtido quando se utilizou solução de diálise sem glicose. O uso de dialisato com glicose a 90 mg/dL não produziu glicemias intradialíticas mais elevadas do que as outras soluções de diálise.
INTRODUCTION: Hypoglycemia can occur during hemodialysis in diabetic chronic renal failure patients when using a dialysate without glucose. With dialysis solutions with glucose 90 mg/dL or more, this is preventable, but diabetic patients could present higher intradialytic glycemias. OBJECTIVE: We tested a dialytic fluid with a lower level of glucose trying to prevent both hypo and hyperglycemia in these patients. METHODS: Twenty diabetic individuals from our hemodialysis unit were submitted to 3 sessions with dialysis solutions with two different glucose concentrations - 55 mg/dL (Phase 55), and 90 mg/dL (Phase 90) - and a glucose-free one (Phase ZERO). Plasma glucose levels were measured at five moments during each session - before and at 30, 60, 90 and 240 min. Results under 70 mg/dL were considered as hypoglycemia. RESULTS: Three patients presented 6 episodes of hypoglycemia in Phase 55, but no patient presented any episode in Phase 90. In Phase ZERO, five patients presented 7 episodes. CONCLUSION: This dialysate with a low level of glucose (55 mg/dL) did not prevent hypoglycemia episodes during hemodialysis in diabetic patients, these occurrences being similar to that when using a dialysate without glucose. The use of a 90 mg/dL glucose dialysis solution did not induce higher intradialytic glycemia levels than the other dialysis solutions.
Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Glicemia/análise , Diabetes Mellitus/sangue , Soluções para Diálise/química , Glucose/análise , Hipoglicemia/epidemiologia , Diálise Renal , Fatores de Risco , Fatores de TempoRESUMO
Clínica Las Condes tiene un activo programa de trasplante hepático. Como parte de éste nos vemos enfrentados cada vez con mayor frecuencia a manejar pacientes con insuficiencias hepáticas fulminantes(IHF). Esta condición aún mantiene elevadísimos niveles de mortalidad. Ultimamente se han desarrollado nuevos procedimientos que buscan remover las toxinas involucradas en esta condición clínica, y así permitirle al paciente ganar tiempo vital a la espera de que su hígado se recupere o bien pueda ser reemplazado por otro órgano. Como parte de ellas se desarrolló el MARS (Molecular Adsorbent Recirculating System), que consiste en someter a la sangre del paciente a una diálisis con Albúmina, para así depurar las toxinas que se acumulan en las IHF. El presente artículo pretende, a través de una experiencia clínica vivida en nuestra institución, revisar el tema de la IHF, las técnicas actualmente disponibles para su manejo y comunicar al resto del equipo médico que contamos con una valiosa herramienta para manejar a los pacientes que no sean referidos con esta grave condición.
Assuntos
Humanos , Adulto , Feminino , Albuminas/administração & dosagem , Albuminas/uso terapêutico , Insuficiência Hepática/sangue , Insuficiência Hepática/terapia , Chile , Diálise/métodos , Transplante de Fígado , Soluções para Diálise/químicaRESUMO
La existencia de un estado óseo de bajo remodelado no relacionado con el aluminio ha ido adquiriendo importancia en los últimos años. La demostración de unos valores de PTHi excesivamente disminuidos permiten identificar con gran valor predictivo a este grupo de pacientes con especial riesgo de desarrollar una enfermedad ósea adinámica. Aparte del correcto manejo de los factores de riesgo previamente expuestos, existen pocas posibilidades más para actuar sobre el remodelado óseo. Una de ellas sería modificar la concentración de calcio en el dializado, aunque existe poca información sobre su repercusión a largo plazo sobre la masa ósea. El objetivo del presente estudio fue valorar el efecto a largo plazo de la disminución de concentración de calcio del líquido de diálisis de 3,5 a 3 mEq/L sobre la masa ósea y la actividad paratiroidea en los pacientes con hipoparatiroidismo. Se han estudiado 19 pacientes con PTHi < 120 pg/ml y calcemia entre8,5 y 10,5 mg/dl, sin evidencia de intoxicación alumínica. Se han controlado los valores de Ca, P, fosfatasa alcalina, aluminio, PTHi y dosis de diálisis cada (..) (AU)
The existance of a low-bone turnover, non-aluminium related, has been more prevalent in recent years. Factors involved include the increasing number of older and diabetic patients initiating dialysis. Also higher intake of calcium salts and the widespread use of vitamin D derivates may play a role. Demonstration of low PTH secretion allows the recognition of the group of patients with special risk of adynamic bone disease. Little can be done to improve bone remodelling apart from correct management of risk factors previously mentioned. Adecrease in dialysate calcium concentration can act in this way, but the long term effect of this procedure on bone mineral density has scarcely been established. The aim of this study was to evaluate the long term effect of lowering the dialysate calcium concentration from 3.5 to 3 mEq/L on bone mass and PTH activity in patients with hypoparathyroidism. We studied 19 patients with PTH < 120 pg/ml and calcemia between 8.5 and 10.5 mg/dl, without aluminium intoxication. Blood levels of Ca, P, alkaline phosphatase, aluminium, iPTH and dialysis doses were measured every 4 months during the two years of follow-up. Phosphate binders were closely monitored. Also calcium dietary feeding was measured by a 5-day dietetic registry at the beginning and 6 and 12 months later. Bone mineral density was (..) (AU)
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Osso e Ossos , Osso e Ossos/metabolismo , Soluções para Diálise/química , Hipoparatireoidismo/metabolismo , Fatores de TempoRESUMO
Los objetivos del estudio fueron calcular el volumen residual peritoneal (VR) y analizar la relación de VR con el volumen de drenaje (VD).Se analizaron 22 determinaciones de VR, 12 a partir del drenaje de la noche y 10 a partir del drenaje del TER (Test de equilibrio peritoneal), realizado en nueve pacientes en diálisis peritoneal. Se calcula VR=Vinf*(S3-S2)/(SI-S3), donde Vinf es el volumen de infusión peritoneal, S1 las concentraciones de soluto en el drenaje nocturno o del TER, S2 en el baño "limpio" y S3 en el TEP=O (10 min) o infusión después del TEP. Se estudian los solutos urea, creatinina, glucosa, potasio y albúmina. Se analizan las concentraciones de solutos en las bolsas "limpias" de dializado del TEP y en la posterior, para detectar interferencias de la glucosa en las concentraciones de solutos.Los valores promedio de VR oscilaron entre 2,11 dl calculado para la creatinina y 3,41 dl para la albúmina, con una media de los cinco solutos de 2,66ñ1,09 dl. Se observa una correlación negativa entre VR y VD para la creatinina (r=0,49, p=0,019) y la media de los cinco solutos (r=0,53, p=0,020). Los valores de VD y los de VR para los cinco solutos no presentan diferencias entre los procedentes del inicio y del final del TEP. La distinta composición encontrada por otros autores de la bolsa de dializado del TER podría explicar las diferencias en los cálculos de VR respecto a los valores de este estudio. (AU)